Match tier
Listed
Presence
Current · Arkansas
Last published
2026
Sources
OpenAlex · ORCID
Refreshed
2026-08-15
N
Nathan L. Avaritt
Researcher
Also affiliated: Arkansas Children's Hospital (2020–2023); University of California, Los Angeles (2022); Winthrop Rockefeller Foundation (2022–2023); Arkansas Department of Agriculture (2011)
Faculty Researcher
7 h-index
45 pubs
215 cited
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Nathan L. Avaritt's research investigates mechanisms underlying melanoma progression and potential therapeutic interventions. His work includes studying the impact of epigenetic regulators, such as EZH2, on melanoma cells, particularly in the context of metabolic stress and the restoration of MHC class I expression. Avaritt also explores novel anti-melanoma agents, including natural compounds derived from fungi and synthetic analogues. His research extends to investigating how genetic factors, like S100b suppression via CRISPR/dCas9-KRAB, can restore p53-mediated apoptosis in melanoma cells, and how ATF6 activation influences response to immune checkpoint blockade (ICB) therapy. Additionally, Avaritt has explored the effects of C-section on gut microbiota composition in mice and the protective role of factor XI inhibition in a baboon model of sepsis. He has published 45 papers, with a total of 210 citations and an h-index of 7. Key collaborators include Alan J. Tackett, Billie Heflin, Brian Koss, and Sanjay Adhikary, all from the University of Arkansas for Medical Sciences.
Metrics
- h-index: 7
- Publications: 45
- Citations: 215
Selected Publications
-
Abstract 6545: Characterizing ATF6 activation-driven mechanisms improving ICB efficacy (2026)
-
Abstract 6079: Resistance-specific proteogenomics in melanoma PDXs (2026)
-
691 ATF6 activation promotes ICB response in melanoma (2025)
-
Anthrax toxins exacerbate sepsis-induced coagulopathy and endothelial dysfunction in a baboon model of anthrax (2025)
-
Protective effects of factor XI inhibition by abelacimab in a baboon model of live Staphylococcus aureus sepsis (2025)
-
EZH2 loss during metabolic stress drives restoration of MHC class I machinery in melanoma (2025)
-
Abstract 4622: Proteomic insights into anti-CTLA4 therapy resistance in metastatic melanoma: Pathway-specific biomarkers for treatment response (2025)
-
Correction: Thiazole-fused androstenone and ethisterone derivatives: potent β- and γ-actin cytoskeleton inhibitors to treat melanoma tumors (2025)
-
Thiazole-fused androstenone and ethisterone derivatives: potent β- and γ-actin cytoskeleton inhibitors to treat melanoma tumors (2024)
-
538 ATF6 activation in melanoma promotes anti-tumor immunity and improves ICB therapy response (2024)
-
Synthesis and Anti‐Melanoma Activity of Acryloyl Pyridinone Analogues (2023)
-
Supplementary Data from Raman Spectroscopy and Machine Learning Reveals Early Tumor Microenvironmental Changes Induced by Immunotherapy (2023)
-
Data from Raman Spectroscopy and Machine Learning Reveals Early Tumor Microenvironmental Changes Induced by Immunotherapy (2023)
-
Supplementary Data from Raman Spectroscopy and Machine Learning Reveals Early Tumor Microenvironmental Changes Induced by Immunotherapy (2023)
-
Data from Raman Spectroscopy and Machine Learning Reveals Early Tumor Microenvironmental Changes Induced by Immunotherapy (2023)
Grants & Funding
As listed on this researcher's institutional profile.
- Proteogenomic analysis of responders versus nonresponders in a Phase I clinical trial of Th17-inducing dendritic cell vaccination for advanced stage ovarian cancer US Department of Defense
- Development of MassSQUIRM to Quantitatively Measure Lysine Methylation NIH
- Development of technology for high resolution epigenetic profiling of chromatin NIH
Collaboration Network
Top Collaborators
Alan J. Tackett
University of Arkansas for Medical Sciences
20 shared publications
In database
- The mycelium of the Trametes versicolor synn. Coriolus versicolor (Turkey tail mushroom) exhibit anti-melanoma activity in vitro
- CRISPR/dCas9-KRAB-Mediated Suppression of S100b Restores p53-Mediated Apoptosis in Melanoma Cells
- Protective effects of factor XI inhibition by abelacimab in a baboon model of live Staphylococcus aureus sepsis
- Synthesis and Anti‐Melanoma Activity of Acryloyl Pyridinone Analogues
- EZH2 loss during metabolic stress drives restoration of MHC class I machinery in melanoma
Showing 5 of 20 shared publications
Stephanie D. Byrum
University of Arkansas for Medical Sciences
12 shared publications
In database
- Cutting-Edge Technologies Driving Quantitative Mass Spectrometry
- Integrative Proteomics and Phosphoproteomics of Asthmatic Airways following RV Infection
- Proteogenomics analysis to identify acquired resistance-specific alterations in melanoma PDXs on MAPKi therapy
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Reference Database Protocol v1
Showing 5 of 12 shared publications
Samuel G. Mackintosh
University of Arkansas for Medical Sciences
6 shared publications
In database
- Protective effects of factor XI inhibition by abelacimab in a baboon model of live Staphylococcus aureus sepsis
- Proteogenomics analysis to identify acquired resistance-specific alterations in melanoma PDXs on MAPKi therapy
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Analysis to Identify Acquired Resistance-Specific Alterations in Melanoma PDXs on MAPKi Therapy
Showing 5 of 6 shared publications
Billie Heflin
University of Arkansas for Medical Sciences
6 shared publications
In database
- The mycelium of the Trametes versicolor synn. Coriolus versicolor (Turkey tail mushroom) exhibit anti-melanoma activity in vitro
- CRISPR/dCas9-KRAB-Mediated Suppression of S100b Restores p53-Mediated Apoptosis in Melanoma Cells
- Synthesis and Anti‐Melanoma Activity of Acryloyl Pyridinone Analogues
- EZH2 loss during metabolic stress drives restoration of MHC class I machinery in melanoma
- 538 ATF6 activation in melanoma promotes anti-tumor immunity and improves ICB therapy response
Showing 5 of 6 shared publications
Brian Koss
University of Arkansas for Medical Sciences
5 shared publications
In database
- CRISPR/dCas9-KRAB-Mediated Suppression of S100b Restores p53-Mediated Apoptosis in Melanoma Cells
- EZH2 loss during metabolic stress drives restoration of MHC class I machinery in melanoma
- Abstract 1892: Proteomic interrogation of the metabolic control of MHC class I antigen presentation in metastatic melanoma
- 538 ATF6 activation in melanoma promotes anti-tumor immunity and improves ICB therapy response
- 691 ATF6 activation promotes ICB response in melanoma
Kanishka Manna
University of Arkansas for Medical Sciences
4 shared publications
In database
- Proteogenomics analysis to identify acquired resistance-specific alterations in melanoma PDXs on MAPKi therapy
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Analysis to Identify Acquired Resistance-Specific Alterations in Melanoma PDXs on MAPKi Therapy
Prashanthi Dharanipragada
University of California, Los Angeles (US)
4 shared publications
- Proteogenomics analysis to identify acquired resistance-specific alterations in melanoma PDXs on MAPKi therapy
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Analysis to Identify Acquired Resistance-Specific Alterations in Melanoma PDXs on MAPKi Therapy
Duah Alkam
University of Arkansas for Medical Sciences
4 shared publications
In database
- Proteogenomics analysis to identify acquired resistance-specific alterations in melanoma PDXs on MAPKi therapy
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Analysis to Identify Acquired Resistance-Specific Alterations in Melanoma PDXs on MAPKi Therapy
Charity L. Washam
University of Arkansas for Medical Sciences
4 shared publications
In database
- Proteogenomics analysis to identify acquired resistance-specific alterations in melanoma PDXs on MAPKi therapy
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Analysis to Identify Acquired Resistance-Specific Alterations in Melanoma PDXs on MAPKi Therapy
Michael S. Robeson
University of Arkansas for Medical Sciences
4 shared publications
In database
- Proteogenomics analysis to identify acquired resistance-specific alterations in melanoma PDXs on MAPKi therapy
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Analysis to Identify Acquired Resistance-Specific Alterations in Melanoma PDXs on MAPKi Therapy
Zhentao Yang
University of California, Los Angeles (US)
4 shared publications
- Proteogenomics analysis to identify acquired resistance-specific alterations in melanoma PDXs on MAPKi therapy
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Analysis to Identify Acquired Resistance-Specific Alterations in Melanoma PDXs on MAPKi Therapy
Shirley H. Lomeli
University of California, Los Angeles (US)
4 shared publications
- Proteogenomics analysis to identify acquired resistance-specific alterations in melanoma PDXs on MAPKi therapy
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Analysis to Identify Acquired Resistance-Specific Alterations in Melanoma PDXs on MAPKi Therapy
Gatien Moriceau
4 shared publications
- Proteogenomics analysis to identify acquired resistance-specific alterations in melanoma PDXs on MAPKi therapy
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Analysis to Identify Acquired Resistance-Specific Alterations in Melanoma PDXs on MAPKi Therapy
Santosh Kumar Paidi
Johns Hopkins University (US)
4 shared publications
- Data from Raman Spectroscopy and Machine Learning Reveals Early Tumor Microenvironmental Changes Induced by Immunotherapy
- Supplementary Data from Raman Spectroscopy and Machine Learning Reveals Early Tumor Microenvironmental Changes Induced by Immunotherapy
- Data from Raman Spectroscopy and Machine Learning Reveals Early Tumor Microenvironmental Changes Induced by Immunotherapy
- Supplementary Data from Raman Spectroscopy and Machine Learning Reveals Early Tumor Microenvironmental Changes Induced by Immunotherapy
Joel Rodríguez Troncoso
University of Arkansas at Fayetteville
4 shared publications
In database
- Data from Raman Spectroscopy and Machine Learning Reveals Early Tumor Microenvironmental Changes Induced by Immunotherapy
- Supplementary Data from Raman Spectroscopy and Machine Learning Reveals Early Tumor Microenvironmental Changes Induced by Immunotherapy
- Data from Raman Spectroscopy and Machine Learning Reveals Early Tumor Microenvironmental Changes Induced by Immunotherapy
- Supplementary Data from Raman Spectroscopy and Machine Learning Reveals Early Tumor Microenvironmental Changes Induced by Immunotherapy
Similar Researchers
Based on overlapping research topics
Alexander Rivas
University of Arkansas for Medical Sciences
Cancer-related molecular mechanisms research
Gut microbiota and health
Immune Response and Inflammation
lan J Tackett
University of Arkansas for Medical Sciences
Cancer-related molecular mechanisms research
Cancer Treatment and Pharmacology
Immune Response and Inflammation
Katherine Wallis
University of Arkansas for Medical Sciences
Cancer-related molecular mechanisms research
Metabolomics and Mass Spectrometry Techniques
Cancer Treatment and Pharmacology
Ruud P.M. Dings
University of Arkansas for Medical Sciences
Cancer-related molecular mechanisms research
Cancer Treatment and Pharmacology
Gut microbiota and health
Alexia S. Terry
University of Arkansas for Medical Sciences
Cancer-related molecular mechanisms research
Cancer Treatment and Pharmacology
Gut microbiota and health
Sabrina P. Trudo
University of Arkansas at Fayetteville
Metabolomics and Mass Spectrometry Techniques
Gut microbiota and health
Immune Response and Inflammation